Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dexamethasone, Cytarabine, Cisplatin and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (Nivo-DHAP-cHL)

Trial Profile

Dexamethasone, Cytarabine, Cisplatin and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (Nivo-DHAP-cHL)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 26 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cisplatin (Primary) ; Cytarabine (Primary) ; Dexamethasone (Primary) ; Nivolumab (Primary)
  • Indications Hodgkin's disease
  • Focus Therapeutic Use
  • Acronyms Nivo-DHAP-cHL

Most Recent Events

  • 20 Sep 2023 Status changed from recruiting to completed.
  • 31 Oct 2022 Planned primary completion date changed from 31 Dec 2021 to 31 Dec 2022.
  • 17 Jun 2021 Preliminary results (n=20) assessing safety and efficacy of Nivo-DHAP combination as a bridge to autoHSCT in patients with R/R cHL presented at the 26th Congress of the European Haematology Association

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top